3-(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl) -3-hydroxybenzyl)-N-alkyl-N-arylbenzamides: Potent, non-peptidic agonists of both the μ and δ opioid receptors

Journal of Medicinal Chemistry

Volumn 46, Issue 4, 2003, Pages 623-633

  Bishop, Michael J ^a   Garrido, Dulce M ^a   Boswell, G Evan ^a   Collins, Mark A ^a   Harris, Philip A ^a   McNutt, Robert W ^b   O'Neill, Scott J ^b   Wei, Ke ^b   Chang, Kwen Jen ^b  

^a GLAXOSMITHKLINE   (United States)

^b Ardent Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL N METHYL N PHENYLBENZAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N (2 FLUOROPHENYL) N METHYLBENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N (3 FLUOROPHENYL) N METHYLBENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N (4 CHLOROPHENYL) N METHYLBENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N (4 METHOXYPHENYL) N METHYLBENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N 4 FLUOROPHENYL N METHYLBENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N CYCLOPROPYL N PHENYLBENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N ETHYL N (4 FLUOROPHENYL)BENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N ETHYL N PHENYLBENZAMIDE; [(4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N METHYL N (4 NITROPHENYL)BENZAMIDE; ANALGESIC AGENT; ANILIDE; BENZAMIDE DERIVATIVE; DELTA OPIATE RECEPTOR; DIETHYLAMINE; MU OPIATE RECEPTOR; OPIATE; UNCLASSIFIED DRUG; 3 (ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL) N (4 FLUOROPHENYL) N METHYLBENZAMIDE; 3-(ALPHA-(4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-HYDROXYBENZYL)-N-(4-FLUOROPHENYL)-N-METHYLBENZAMIDE; PIPERAZINE DERIVATIVE;

ANALGESIC ACTIVITY; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG SYNTHESIS; GUINEA PIG; ILEUM; MOUSE; NONHUMAN; PAIN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; VAS DEFERENS; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; MALE; MUSCLE CONTRACTION; PHYSIOLOGY; SMOOTH MUSCLE; STEREOISOMERISM; SYNTHESIS;

ANIMALS; BENZAMIDES; GUINEA PIGS; ILEUM; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PIPERAZINES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 0037434437     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020395s     Document Type: Article

References (49)

1. (a) Parrot, T. Using opioid analgesics to manage chronic non-cancer pain in primary care. J. Am. Board Fam. Pract. 1999, 12, 293-306.
2. (b) Jadad, A. R.; Browman, G. P. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. J. Am. Med. Assoc. 1995, 274, 1870-1873.
3. Duthie, D. J. R.; Nimmo, W. S. Adverse effects of opioid analgesic drugs. Br. J. Anaesth. 1987, 59 (1), 61-77.
4. Simon, E. J.; Gioannini, T. L. Opiate receptor multiplicity: isolation, purification, and chemical characterization of binding sites. In Opioids I; Herz, A., Ed.; Springer-Verlag: Berlin, 1993; pp 3-21.
5. (a) Clark, J. A.; Liu, L.; Price, M.; Hersh, B.; Edelson, M.; Pasternak, G. W. Kappa opiate receptor multiplicity: evidence for two U50,488 sensitive κ1 subtypes and a novel κ3 subtype. J. Pharmacol. Exp. Ther. 1989, 251, 461-468.
6. (b) Mattia, A.; Vanderah, T.; Mosberg, H. I.; Porreca, F. Lack of antinociceptive cross-tolerance between enkephalin and deltorphin II in mice: evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 258, 583-587.
7. 1 opioid receptor agonists and antagonists. J. Med Chem. 1993, 36, 2572-2574.
8. (d) Rothman, R. B.; Bykov, V.; Xue, B. G.; Xu, H.; de Costa, B. R.; Jacobson, A. E.; Rice, K C.; Kleinman, J. E.; Brady, L. S. Interactions of opiate peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences. Peptides 1992, 13, 977-987.
9. For an extensive two-part review on the development of δ opioid receptor ligands, see the following. (a) Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ-opioid agonists and antagonists (Part II). Expert Opin. Ther. Pat. 1999, 9, 353-374. (b) Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ-opioid agonists and antagonists. Expert Opin. Ther. Pat. 1997, 7, 1075-1098.
10. For an extensive two-part review on the development of δ opioid receptor ligands, see the following. (a) Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ-opioid agonists and antagonists (Part II). Expert Opin. Ther. Pat. 1999, 9, 353-374. (b) Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ-opioid agonists and antagonists. Expert Opin. Ther. Pat. 1997, 7, 1075-1098.
11. Zimmerman, D. M.; Leander, J. D. Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents. J. Med. Chem. 1990, 33, 895-902.
12. Portoghese, P. S.; Sultana, M.; Takemori, A. E. Naltrindole, a highly selective and potent nonpeptide δ opioid receptor antagonist. Eur. J. Pharmacol. 1988, 146, 185-186.
13. (a) Dappen, M. S.; Pitzele, B. S.; Rafferty, M. F. U.S. Patent 5,-223,507, 1993; Chem. Abstr. 1993, 119, 152105.
14. (b) Schmidhammer, H. PCT Application: WO9531464, 1995; Chem. Abstr. 1995, 124, 176606.
15. (a) Dondio, G.; Clarke, G. D.; Giardina, G.; Petrillo, P.; Petrone, G.; Ronzoni, S.; Visentin, L.; Vecchietti, V. The role of the "spacer" in the octahydroisoquinoline series: Discovery of SB 213698, a non-peptidic, potent and selective delta opioid agonist. Analgesia 1995, 1, 394-399.
16. (b) Nagase, H.; Wakita, H.; Kawai, K.; Endo, T.; Matsumoto, O. Patent JP 04275288 A2, 1992; Chem. Abstr. 1992, 119, 49376.
17. Tsushima, M.; Tadauchi, K.; Asai, K.; Miike, N.; Imai, M.; Kudo, T. PCT Int. Appl. WO 0160796 Al, 2001; Chem. Abstr. 2001, 135, 195564.
18. Chang, K.-J.; Rigdon, G. C.; Howard, J. L.; McNutt, R. W. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J. Pharmacol. Exp. Ther. 1993, 267, 852-857.
19. Comer, S. D.; Hoenicke, E. M.; Sable, A. I.; McNutt, R. W.; Chang, K.-J.; de Costa, B. R.; Mosberg, H. I.; Woods, J. H. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J. Pharmacol. Exp. Ther. 1993, 267, 888-895.
20. O'Neill, S. J.; Collins, M. A.; Pettit, H. O.; McNutt, R. W.; Chang, K.-J. Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. J. Pharmacol. Exp. Ther. 1997, 282, 271-277.
21. (a) Vaught, J. L.; Takemori, A. E. Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J. Pharmacol. Exp. Ther. 1979, 208, 86-90.
22. (b) Heyman, J. S.; Jiang, Q.; Rothman, R. B.; Mosberg, H. I.; Porreca, F. Modulation of mu-mediated antinociception by delta-agonists: characterization with antagonists. Eur. J. Pharmacol. 1989, 169, 43-52.
23. (c) Lee, P. H. K.; McNutt, R. W.; Chang, K.-J. A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat. J. Pharmacol. Exp. Ther. 1993, 267, 883-887.
24. (d) Kieffer, B. L.; Gaveriaux-Ruff, C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 2002, 6, 285-306.
25. Su, Y.-F.; McNutt, R. W.; Chang, K.-J. Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J. Pharmacol. Exp. Ther. 1998, 287, 815-823.
26. There have been reports of successful in vivo experiments with compounds that have mixed μ agonist/δ antagonist profiles. For instance, see the following. (a) Schiller, P. W.; Weltrowska, G.; Schmidt, R.; Nguyen, T. M.-D.; Berezowska, I.; Lemieux, C.; Chung, N. N.; Carpenter, K. A.; Wilkes, B. C. Four different types of opioid peptides with mixed μ agonist/δ antagonist properties. Analgesia 1995, 1 (4-6), 703-706. (b) Wells, J. L.; Bartlett, J. L.; Ananthan, S.; Bilsky, E. J. In vivo pharmacological characterization of SORI 9409, a nonpeptidic opioid μ-agonist/δ-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J. Pharmacol. Exp. Ther. 2001, 297 (2), 597-605.
27. There have been reports of successful in vivo experiments with compounds that have mixed μ agonist/δ antagonist profiles. For instance, see the following. (a) Schiller, P. W.; Weltrowska, G.; Schmidt, R.; Nguyen, T. M.-D.; Berezowska, I.; Lemieux, C.; Chung, N. N.; Carpenter, K. A.; Wilkes, B. C. Four different types of opioid peptides with mixed μ agonist/δ antagonist properties. Analgesia 1995, 1 (4-6), 703-706. (b) Wells, J. L.; Bartlett, J. L.; Ananthan, S.; Bilsky, E. J. In vivo pharmacological characterization of SORI 9409, a nonpeptidic opioid μ-agonist/δ-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J. Pharmacol. Exp. Ther. 2001, 297 (2), 597-605.
28. (a) Portoghese, P. S.; Sultana, M.; Nagase, H.; Takemori, A. E. J. Med. Chem. 1988, 31 (2), 281-282.
29. (b) Schwyzer, R. Molecular mechanism of opioid receptor selection. Biochemistry 1986, 25 (20), 6335-6342.
30. Dondio, G.; Ronzoni, S.; Eggleston, D. S.; Artico, M.; Petrillo, P.; Petrone, G.; Visentin, L.; Farina, C.; Vecchietti, V.; Clarke, G. D. Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective δ opioid agonists, based on an extension of the message-address concept. J. Med. Chem. 1997, 40 (20), 3192-3198.
31. Bubacz, D. G.; Davis, A. O.; Dickerson, S. H.; Harris, P. A.; McNutt, R. W.; Collins, M. A.; Chang, K.-J. Synthesis of novel mixed delta-mu opioid agonists. Abstracts of Papers, 213th National Meeting of the American Chemical Society, San Francisco, CA, 1997; MEDI-050.
32. (a) Bishop, M. J.; McNutt, R. W. An efficient synthesis of the benzhydrylpiperazine delta opioid agonist (+)-BW373U86. Bioorg. Med. Chem. Lett. 1995, 5, 1311-1314.
33. (b) Delorme, D.; Berthelette, C.; Lavoie, R.; Roberts, E. Asymmetric synthesis of diarylmethylamines: preparation of selective opioid delta receptor ligands. Tetrahedron: Asymmetry 1998, 9, 3963-3966.
34. X-ray crystallography and structural determination of compound 24 were performed by Dr. Steven J. Geib at the University of Pittsburgh Chemistry X-Ray Diffraction Facility using a Siemens P3 single-crystal diffractometer. See Supporting Information for details.
35. Calderon, S. N.; Rice, K. C.; Rothman, R. B.; Porreca, F.; Flippen-Anderson, J. L.; Kayakiri, H.; Xu, H.; Becketts, K.; Smith, L. E.; Bilsky, E. J.; Davis, P.; Horvath, R. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective δ agonist (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5- dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and related novel non-peptide δ opioid receptor ligands. J. Med. Chem. 1997, 40 (5), 695-704.
36. Calderon, S. N.; Rothman, R. B.; Porreca, F.; Flippen-Anderson, J. L.; McNutt, R. W.; Xu, H.; Smith, L. E.; Bilsky, E. J.; Davis, P.; Rice, K. C. Probes for Narcotic Mediated Phenomena. 19. Synthesis of (+)-4-[(αR)-α((2S,5R)-4-Allyl-2,5- dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A highly selective, nonpeptide delta opioid receptor agonist. J. Med. Chem. 1994, 37, 2125-2128.
37. For an early example of this type of displacement, see the following. Newman, M. S. The preparation of naphthonitrile. J. Am. Chem. Soc. 1937, 59, 2472.
38. Wissner, A.; Grudzinskas, C. V. Reaction of tert -butyldimethylsilyl esters with oxalyl chloride - dimethylformamide: preparation of carboxylic acids under neutral conditions. J. Org. Chem. 1978, 43, 3972-3974.
39. Krishnamurthy, S. A highly efficient and general N-monomethylation of functionalized primary amines via formylation - borane:methyl sulfide reduction. Tetrahedron Lett. 1982, 23, 3315-3318.
40. Chien, P.; Cheng, C. C. 2,8-Bis(substituted amino)phenothiazine 5,5-dioxides. J. Med. Chem. 1966, 9, 960-962.
41. Review: Abramovitch, R. A.; Barton, D. H.; Finet, J.-P. Newer methods of arylation. Tetrahedron 1988, 44, 3039-3071.
42. Ellefson, C. R.; Cusic, J. W. Some 10-substituted 5-ethyl-10-dialkylaminoalkyl-10,11-dihydro-5H-dibenz[b,f]azepines as potential antiarrythmic agents. J. Med. Chem. 1976, 19, 1345-1349.
43. Kramer, T. H.; Davis, P.; Hruby, V. J.; Burks, T. F.; Porreca, F. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands. J. Pharmacol. Exp. Ther. 1993, 266 (2), 577-584.
44. (a) See ref 6 for a discussion of potency discrepancies in opioid assays.
45. (b) Adham, N.; Zgombick, J. M.; Bard, J.; Branchek, T. A. Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation. J. Pharmacol. Exp. Ther. 1998, 287, 508-514.
46. Lord, J. A. H.; Waterfield, A. A.; Hughes, J.; Kosterlitz, H. W. Endogenous opioid peptides: multiple agonists and receptors. Nature 1977, 267 (5611), 495-499.
47. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-253.
48. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3089-3108.
49. Ibbitson, D. A.; Grocock, D. E.; Hallas, G.; Hepworth, J. D.; Hudson, J. A. The ortho-effect in 2-amino- and 2-(methylamino)-benzylidyne trifluoride (2-trifluoromethyl- and 2-trifluoromethyl-N-methylamine). J. Chem. Soc. B 1971, 457-459.